

Simon A Rule

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1886743/publications.pdf>

Version: 2024-02-01

125
papers

7,102
citations

116194

36
h-index

66518

82
g-index

126
all docs

126
docs citations

126
times ranked

6418
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. <i>Haematologica</i> , 2022, 107, 500-509.	1.7	5
2	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	3.3	56
3	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021, 137, 877-887.	0.6	68
4	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. <i>British Journal of Haematology</i> , 2021, 193, 290-298.	1.2	32
5	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
6	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
7	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	2.5	60
8	Mantle Cell Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 163-178.	0.2	0
9	The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1035-1038.	1.2	10
10	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13
11	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15
12	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	2.2	119
13	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3188-3197.	0.6	26
14	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 923-939.	0.9	1
15	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 348-356.	1.0	2
16	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
17	Phase 1b Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46
18	OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. <i>Hematological Oncology</i> , 2019, 37, 46-47.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
20	The modern approach to mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 66-69.	0.8	22
21	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , 2019, 36, 93.	1.7	4
22	LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 142-143.	0.8	1
23	NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-CT GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 67-68.	0.8	10
24	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 244-245.	0.8	3
25	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 999-1005.	1.2	29
26	Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1002-1004.	1.2	2
27	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019, 104, e211-e214.	1.7	122
28	Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 421-434.	1.8	5
29	Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia</i> , 2019, 33, 969-980.	3.3	97
30	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019, 184, 558-569.	1.2	71
31	40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study. <i>Blood</i> , 2019, 134, 2821-2821.	0.6	7
32	Does maintenance therapy have a role in mantle cell lymphoma treatment?. <i>Expert Review of Hematology</i> , 2018, 11, 285-292.	1.0	1
33	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	3.3	67
34	Can we improve on ibrutinib in mantle cell lymphoma?. <i>Lancet Haematology</i> , 2018, 5, e98-e99.	2.2	0
35	Subcutaneous rituximab can be safely administered without pre-medication. <i>British Journal of Haematology</i> , 2018, 181, 836-837.	1.2	6
36	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , 2018, 391, 659-667.	6.3	324

#	ARTICLE	IF	CITATIONS
37	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	1.2	10
38	What is the optimal initial management of the younger mantle cell lymphoma patient?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 90-98.	0.7	2
39	Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!. <i>Blood</i> , 2018, 132, 2722-2729.	0.6	59
40	Bortezomib-based chemotherapy in mantle cell lymphoma. <i>Lancet Oncology</i> , The, 2018, 19, 1419-1421.	5.1	6
41	Guideline for the management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 46-62.	1.2	38
42	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma â€“ where do they fit in?. <i>Expert Review of Hematology</i> , 2018, 11, 749-756.	1.0	6
43	Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7547-7547.	0.8	11
44	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7588-TPS7588.	0.8	6
45	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. <i>Haematologica</i> , 2017, 102, 765-772.	1.7	21
46	Novel agents in mantle cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 491-506.	1.1	7
47	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	0.6	15
48	Long-term follow-up of patients with CLL treated with the selective Brutonâ€™s tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	0.6	48
49	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
50	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	3.2	135
51	Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. <i>Advances in Therapy</i> , 2017, 34, 2210-2231.	1.3	50
52	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three openâ€™label studies. <i>British Journal of Haematology</i> , 2017, 179, 430-438.	1.2	116
53	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200
54	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. <i>Hematological Oncology</i> , 2017, 35, 143-144.	0.8	4

#	ARTICLE	IF	CITATIONS
55	IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. <i>Hematological Oncology</i> , 2017, 35, 232-233.	0.8	1
56	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv62-iv71.	0.6	387
57	Phase I/II, first in human trial of the Bruton's tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14101-e14101.	0.8	2
58	Phase I/II study of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination in patients with lymphoma or chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7574-TPS7574.	0.8	0
59	Frontline therapy and role of high-dose consolidation in mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 419-424.	0.9	4
60	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
61	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016, 127, 1559-1563.	0.6	228
62	Evolving concepts in tumour lysis syndrome management – response to Aged <i>et al</i> . <i>British Journal of Haematology</i> , 2016, 173, 486-487.	1.2	0
63	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016, 101, 235-240.	1.7	24
64	The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 461-462.	0.6	1
65	Ibrutinib for mantle cell lymphoma. <i>Future Oncology</i> , 2016, 12, 477-491.	1.1	8
66	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.	5.1	373
67	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2016, 387, 770-778.	6.3	389
68	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 rgBT /Overlock 10 Tf	8.1	185
69	A new standard of care for mantle cell lymphoma?. <i>Lancet Oncology</i> , The, 2016, 17, 5-6.	5.1	1
70	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , 2016, 128, 1786-1786.	0.6	6
71	Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial. <i>Blood</i> , 2016, 128, 1855-1855.	0.6	6
72	Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7525-7525.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial.. Journal of Clinical Oncology, 2016, 34, 7570-7570.	0.8	16
74	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. Blood, 2016, 128, 4403-4403.	0.6	0
75	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. Blood, 2016, 128, 2978-2978.	0.6	0
76	Mantle cell lymphoma: evolving management strategies. Blood, 2015, 125, 48-55.	0.6	155
77	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 2015, 126, 739-745.	0.6	349
78	A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management, 2015, 11, 979.	0.9	24
79	Response to the letter from Gozzetti et al. entitled: "Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders". Leukemia and Lymphoma, 2015, 56, 1918-1918.	0.6	0
80	Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. British Journal of Haematology, 2015, 170, 131-134.	1.2	15
81	Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. British Journal of Haematology, 2015, 169, 661-671.	1.2	152
82	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia, 2015, 29, 464-473.	3.3	64
83	Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British Journal of Haematology, 2015, 168, 55-62.	1.2	44
84	How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. Leukemia and Lymphoma, 2015, 56, 1599-1610.	0.6	12
85	Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 2015, 126, 2936-2936.	0.6	2
86	Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood, 2015, 126, 2944-2944.	0.6	23
87	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). Blood, 2015, 126, 469-469.	0.6	3
88	Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology, 2015, 33, LBA7005-LBA7005.	0.8	10
89	Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology, 2015, 33, LBA7005-LBA7005.	0.8	0
90	Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma.. Journal of Clinical Oncology, 2015, 33, 8547-8547.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2015, 126, 2938-2938.	0.6	1
92	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus. <i>Blood</i> , 2015, 126, 1542-1542.	0.6	0
93	Ibrutinib for the treatment of mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2014, 7, 521-531.	1.0	10
94	Management perspective for mantle cell lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 31-40.	0.7	0
95	Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. <i>Journal of Medical Economics</i> , 2014, 17, 459-468.	1.0	55
96	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii83-iii92.	0.6	129
97	Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute. <i>Value in Health</i> , 2014, 17, A537.	0.1	14
98	Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and) Tj ETQq0 0 0 rgBT /Overlock 10 T Results from the Maintenance Phase of the Phase Ib GAUDI Study. <i>Blood</i> , 2014, 124, 1743-1743.	0.6	4
99	The Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , 2014, 124, 3328-3328.	0.6	7
100	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , 2014, 124, 4471-4471.	0.6	19
101	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2014, 124, 78-78.	0.6	23
102	The Brutonâ€™s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8553-8553.	0.8	5
103	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
104	A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkinâ€™s Lymphoma: Interim Safety Data From The Mabcute Study. <i>Blood</i> , 2013, 122, 3052-3052.	0.6	3
105	The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure. <i>Blood</i> , 2013, 122, 3405-3405.	0.6	24
106	Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial. <i>Blood</i> , 2013, 122, 4348-4348.	0.6	3
107	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4397-4397.	0.6	9
108	A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8613-TPS8613.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Guidelines for the investigation and management of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 405-426.	1.2	72
110	Mantle-cell lymphoma in the elderly: is it time to CHOP and change?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1855-1856.	0.6	0
111	Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000). <i>Blood</i> , 2012, 120, 3686-3686.	0.6	4
112	Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. <i>Blood</i> , 2012, 120, 904-904.	0.6	13
113	Velcade combinations in mantle cell lymphoma: are we learning anything?. <i>Leukemia and Lymphoma</i> , 2011, 52, 545-547.	0.6	1
114	Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study. <i>Blood</i> , 2011, 118, 265-265.	0.6	3
115	The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial. <i>Blood</i> , 2011, 118, 440-440.	0.6	9
116	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , 2011, 118, 442-442.	0.6	14
117	Everolimus in relapsed hodgkin lymphoma, something exciting or a case of caveat mTOR?. <i>American Journal of Hematology</i> , 2010, 85, NA-NA.	2.0	1
118	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1419-1427.	2.0	93
119	A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. <i>Blood</i> , 2010, 116, 857-857.	0.6	5
120	Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2010, 116, 3983-3983.	0.6	0
121	Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenström's Macroglobulinaemia.. <i>Blood</i> , 2007, 110, 2559-2559.	0.6	10
122	Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis. <i>Journal of Clinical Oncology</i> , 2007, 25, 17006-17006.	0.8	2
123	Managing cancer-related skeletal events with bisphosphonates. <i>British Journal of Hospital Medicine</i> , 2004, 65, 355-360.	0.3	0
124	Guidelines on the use of colony-stimulating factors in haematological malignancies. <i>British Journal of Haematology</i> , 2003, 123, 22-33.	1.2	35
125	Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. <i>British Journal of Haematology</i> , 1999, 104, 612-613.	1.2	51